Literature DB >> 12366605

A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy.

T Holm1, J F Lassen, S E Husted, P Christensen, L Heickendorff.   

Abstract

OBJECTIVES: To evaluate the effect of a shared care programme (SCP), defined as a scheme based on shared responsibility, enhanced information exchange, continues medical education and explicit clinical guidelines, between general practitioners (GPs) and a hospital outpatient clinic (HOC), on oral anticoagulant therapy (OAT).
DESIGN: The study was a 2-year prospective, randomized, controlled trial, preceded by a 1-year period of observation.
SETTING: The HOC, GPs, and OAT patients in the admission area of Aarhus University Hospital, Aarhus County, Denmark, covering 310 300 inhabitants.
SUBJECTS: A total of 207 GPs, including their enlisted patients on OAT, were invited, and 61.4% accepted participation. They were randomized into an intervention group [group-INT: 64 GPs and 453 patients (170 patients on OAT throughout the study period, i.e. full follow-up)], and a control group [group-CON: 63 GPs and 422 patients (173 with full follow-up)]. The remaining 80 GPs served as a nonresponder group (group-NON) of 485 patients (184 with full follow-up). MAIN OUTCOME MEASURE: Therapeutic control of OAT in terms of time spent by the patients within the therapeutic interval (TI) of an international normalized ratio (INR) between 2.0 and 3.5.
RESULTS: The groups did not differ significantly with regard to age, sex, OAT indication, anticoagulant drug used, or the therapeutic control at baseline. In a comparison based on intention-to-treat principles, the therapeutic control increased statistical significance amongst patients with full follow-up in group-INT compared with group-CON (median time within TI: group INT = 86.6% vs. 80.5%, P = 0.007).
CONCLUSION: An SCP of anticoagulant management is effective in reducing patient time outside the therapeutic INR interval in OAT patients randomly assigned to an SCP, as compared with a control group.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12366605     DOI: 10.1046/j.1365-2796.2002.01039.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  4 in total

1.  HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community.

Authors:  Binyamin Ben Avraham; Marisa Generosa Crespo-Leiro; Gerasimos Filippatos; Israel Gotsman; Petar Seferovic; Tal Hasin; Luciano Potena; Davor Milicic; Andrew J S Coats; Giuseppe Rosano; Frank Ruschitzka; Marco Metra; Stefan Anker; Johann Altenberger; Stamatis Adamopoulos; Yaron D Barac; Ovidiu Chioncel; Nicolaas De Jonge; Jeremy Elliston; Maria Frigeiro; Eva Goncalvesova; Avishay Grupper; Righab Hamdan; Yoav Hammer; Loreena Hill; Osnat Itzhaki Ben Zadok; Miriam Abuhazira; Jacob Lavee; Wilfried Mullens; Sanemn Nalbantgil; Massimo F Piepoli; Piotr Ponikowski; Arsen Ristic; Arjang Ruhparwar; Aviv Shaul; Laurens F Tops; Steven Tsui; Stephan Winnik; Tiny Jaarsma; Finn Gustafsson; Tuvia Ben Gal
Journal:  ESC Heart Fail       Date:  2021-09-14

Review 2.  Frequency of adverse events in patients with poor anticoagulation: a meta-analysis.

Authors:  Natalie Oake; Dean A Fergusson; Alan J Forster; Carl van Walraven
Journal:  CMAJ       Date:  2007-05-22       Impact factor: 8.262

Review 3.  Shared care across the interface between primary and specialty care in management of long term conditions.

Authors:  Susan M Smith; Gráinne Cousins; Barbara Clyne; Shane Allwright; Tom O'Dowd
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

4.  Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH).

Authors:  Saro H Armenian; Lanie Lindenfeld; Aleksi Iukuridze; Meagan Echevarria; Samantha Bebel; Catherine Coleman; Ryotaro Nakamura; Farah Abdullah; Badri Modi; Kevin C Oeffinger; Karen M Emmons; Ashfaq A Marghoob; Alan C Geller
Journal:  BMC Cancer       Date:  2020-08-03       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.